CORE--HYBRIDOMA FACILITY

核心——杂交瘤设施

• 批准号: 6548052
• 负责人: David Alan Fox
• 金额: $ 7.6万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-28 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6548052
• 关键词: B lymphocyte; arthritis; biomedical facility; biotechnology; cell fusion; connective tissue disorder; cryopreservation; density gradient ultracentrifugation; hamsters; hybridomas; immunologic substance development /preparation; laboratory mouse; laboratory rabbit; laboratory rat; monoclonal antibody; tissue /cell preparation; tissue resource /registry

The Hybridoma Core Facility will be used by approximately 30 UM- RDCC investigators who are pursuing a variety of research projects that require monoclonal antibodies. The primary purpose of the Hybridoma Core is to generate somatic-cell hybrids (hybridomas) that produce monoclonal antibodies of desired specificity. It is currently supported by the Michigan Diabetes Research and Training Center (MDRTC), and by the University of Michigan Multipurpose Arthritis Center (UM-MAC), for use by investigators within these centers, t a 20% recharge. It is also used by other investigators on a full recharge basis. Services provided include immunization of mice, fusion of B lymphocytes with myeloma cells to create hybridomas, subcloning and cryopreservation of hybridomas, antibody isotyping production of ascites in mice, and production of antibodies in vitro. Consultation is provided from the Hybridoma Core directors in design of immunization strategies and screening assays to ensure efficient generation and detection of the desired monoclonal strategies and screening to ensure efficient generation and detection of the desired monoclonal antibodies. The majority of hybridomas produced in the core are of murine origin, but rat, hamster and human hybridomas have also been produced. Since its establishment in 1980 the Hybridoma Facility has produced monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, tumor cell antigens, purified proteins, cytokines, hormones, hormone receptors and recombinant proteins. Over the past thirteen years of UM-CAS support (1988-2000) more than 200 fusions were performed for UM-MAC investigators. Subcloning was performed in more than 1000 hybridomas, and more than 1000 monoclonal antibody batches were produced in murine ascites. A variety of specialized procedures have been added during the current funding cycle to address various needs of UM-MAC investigators, and future UM-RDCC investigators. The current proposal will allow this faculty to continue to provide up-to- date hybridoma technology for UM-RDCC laboratories. The core will also provide collaborative and consultative services for the UM-RDCC investigators who may wish to select recombinant antibody-like reagents from phage display libraries. Through these initiatives, the Hybridoma Core will remain on the cutting edge of monoclonal antibody technology, and continued to provide optimal service to a broad range of users.

杂交瘤核心设施将由大约 30 名 UM-RDCC 研究人员使用，他们正在进行各种需要单克隆抗体的研究项目。杂交瘤核心的主要目的是产生体细胞杂交体（杂交瘤），从而产生所需特异性的单克隆抗体。目前它得到密歇根糖尿病研究和培训中心 (MDRTC) 以及密歇根大学多用途关节炎中心 (UM-MAC) 的支持，供这些中心内的研究人员使用，需充值 20%。其他调查员也可以在充满电的基础上使用它。提供的服务包括小鼠免疫、B淋巴细胞与骨髓瘤细胞融合以产生杂交瘤、杂交瘤的亚克隆和冷冻保存、小鼠腹水的抗体同种型生产以及体外抗体生产。杂交瘤核心主管在免疫策略和筛选测定的设计方面提供咨询，以确保有效生成和检测所需的单克隆策略，并进行筛选以确保有效生成和检测所需的单克隆抗体。核心中产生的大多数杂交瘤都是小鼠来源的，但也产生了大鼠、仓鼠和人类杂交瘤。自 1980 年建立以来，杂交瘤设施已生产针对多种淋巴细胞表面抗原、肿瘤细胞抗原、肿瘤细胞抗原、纯化蛋白、细胞因子、激素、激素受体和重组蛋白的单克隆抗体。在过去 13 年的 UM-CAS 支持（1988-2000）中，为 UM-MAC 研究人员进行了 200 多次融合。在1000多个杂交瘤中进行了亚克隆，并在小鼠腹水中产生了1000多个单克隆抗体批次。在当前的资助周期中增加了各种专门程序，以满足 UM-MAC 调查人员和未来 UM-RDCC 调查人员的各种需求。目前的提案将使该教师能够继续为 UM-RDCC 实验室提供最新的杂交瘤技术。该核心还将为希望从噬菌体展示库中选择重组抗体样试剂的 UM-RDCC 研究人员提供协作和咨询服务。通过这些举措，Hybridoma Core将继续处于单克隆抗体技术的前沿，并继续为广大用户提供最优的服务。